{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:18:06Z","timestamp":1794716286116,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T00:00:00Z","timestamp":1509062400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T00:00:00Z","timestamp":1509062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL-006193-4 (Intramural grant to NNM from the NHLBI)."],"award-info":[{"award-number":["HL-006193-4 (Intramural grant to NNM from the NHLBI)."]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12967-017-1321-6","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T05:48:39Z","timestamp":1509083319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":279,"title":["GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk"],"prefix":"10.1186","volume":"15","author":[{"given":"Margery A.","family":"Connelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Otvos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Shalaurova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Playford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal N.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,27]]},"reference":[{"key":"1321_CR1","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1373\/clinchem.2014.232918","volume":"61","author":"JD Otvos","year":"2015","unstructured":"Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, Tracy RP. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem. 2015;61:714\u201323.","journal-title":"Clin Chem"},{"key":"1321_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0014-5793(87)80168-0","volume":"215","author":"JD Bell","year":"1987","unstructured":"Bell JD, Brown JC, Nicholson JK, Sadler PJ. Assignment of resonances for \u2018acute-phase\u2019 glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Lett. 1987;215:311\u20135.","journal-title":"FEBS Lett"},{"key":"1321_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.cels.2015.09.007","volume":"1","author":"SC Ritchie","year":"2015","unstructured":"Ritchie SC, Wurtz P, Nath AP, Abraham G, Havulinna AS, Fearnley LG, Sarin AP, Kangas AJ, Soininen P, Aalto K, et al. The biomarker GlycA is associated with chronic inflammation and predicts long-term risk of severe infection. Cell Syst. 2015;1:293\u2013301.","journal-title":"Cell Syst"},{"key":"1321_CR4","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s10753-014-0107-8","volume":"38","author":"K Dungan","year":"2015","unstructured":"Dungan K, Binkley P, Osei K. GlycA is a novel marker of inflammation among non-critically ill hospitalized patients with type 2 diabetes. Inflammation. 2015;38:1357\u201363.","journal-title":"Inflammation"},{"key":"1321_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13075-015-0646-x","volume":"17","author":"MJ Ormseth","year":"2015","unstructured":"Ormseth MJ, Chung CP, Oeser AM, Connelly MA, Sokka T, Raggi P, Solus JF, Otvos JD, Stein CM. Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis. Arthritis Res Ther. 2015;17:117.","journal-title":"Arthritis Res Ther"},{"key":"1321_CR6","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.clinbiochem.2015.06.016","volume":"48","author":"RP Dullaart","year":"2015","unstructured":"Dullaart RP, Gruppen EG, Connelly MA, Lefrandt JD. A pro-inflammatory glycoprotein biomarker is associated with lower bilirubin in metabolic syndrome. Clin Biochem. 2015;48:1045\u20137.","journal-title":"Clin Biochem"},{"key":"1321_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.clinbiochem.2015.05.001","volume":"48","author":"RP Dullaart","year":"2015","unstructured":"Dullaart RP, Gruppen EG, Connelly MA, Otvos JD, Lefrandt JD. GlycA, a biomarker of inflammatory glycoproteins, is more closely related to the leptin\/adiponectin ratio than to glucose tolerance status. Clin Biochem. 2015;48:811\u20134.","journal-title":"Clin Biochem"},{"key":"1321_CR8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/eci.12481","volume":"45","author":"EG Gruppen","year":"2015","unstructured":"Gruppen EG, Connelly MA, Otvos JD, Bakker SJ, Dullaart RP. A novel protein glycan biomarker and LCAT activity in metabolic syndrome. Eur J Clin Invest. 2015;45:850\u20139.","journal-title":"Eur J Clin Invest"},{"key":"1321_CR9","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jacl.2015.11.009","volume":"10","author":"EG Gruppen","year":"2016","unstructured":"Gruppen EG, Connelly MA, Dullaart RP. Higher circulating GlycA, a pro-inflammatory glycoprotein biomarker, relates to lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in diabetic or metabolic syndrome subjects. J Clin Lipidol. 2016;10:512\u20138.","journal-title":"J Clin Lipidol"},{"key":"1321_CR10","doi-asserted-by":"publisher","DOI":"10.1101\/018655","author":"SC Ritchie","year":"2015","unstructured":"Ritchie SC, Wurtz P, Nath AP, Abraham G, Havulinna AS, Kangas AJ, Soininen P, Aalto K, Seppala I, Raitoharju E, et al. Systems medicine links microbial inflammatory response with glycoprotein-associated mortality risk. BioRxiv. 2015. doi: 10.1101\/018655 .","journal-title":"BioRxiv"},{"key":"1321_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12887-016-0688-5","volume":"16","author":"MA Connelly","year":"2016","unstructured":"Connelly MA, Shimizu C, Winegar DA, Shalaurova I, Pourfarzib R, Otvos JD, Kanegaye JT, Tremoulet AH, Burns JC. Differences in GlycA and lipoprotein particle parameters may help distinguish acute Kawasaki Disease from other febrile illnesses in children. BMC Pediatr. 2016;16:151.","journal-title":"BMC Pediatr"},{"issue":"3","key":"1321_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2337\/dc16-1569","volume":"40","author":"C Lorenzo","year":"2017","unstructured":"Lorenzo C, Festa A, Hanley AJ, Rewers MJ, Escalante A, Haffner SM. Novel protein glycan-derived markers of systemic inflammation and C-reactive protein in relation to glycemia, insulin resistance, and insulin secretion. Diabetes Care. 2017;40(3):375\u201382.","journal-title":"Diabetes Care"},{"key":"1321_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cca.2016.06.012","volume":"459","author":"MA Connelly","year":"2016","unstructured":"Connelly MA, Gruppen EG, Otvos JD, Dullaart RP. Inflammatory glycoproteins in cardiometabolic disorders, autoimmune diseases and cancer. Clin Chim Acta. 2016;459:177\u201386.","journal-title":"Clin Chim Acta"},{"key":"1321_CR14","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1373\/clinchem.2016.261636","volume":"63","author":"RW McGarrah","year":"2017","unstructured":"McGarrah RW, Kelly JP, Craig DM, Haynes C, Jessee RC, Huffman KM, Kraus WE, Shah SH. A novel protein glycan-derived inflammation biomarker independently predicts cardiovascular disease and modifies the association of HDL subclasses with mortality. Clin Chem. 2017;63:288\u201396.","journal-title":"Clin Chem"},{"key":"1321_CR15","doi-asserted-by":"publisher","first-page":"e001221","DOI":"10.1161\/JAHA.114.001221","volume":"3","author":"AO Akinkuolie","year":"2014","unstructured":"Akinkuolie AO, Buring JE, Ridker PM, Mora S. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc. 2014;3:e001221.","journal-title":"J Am Heart Assoc"},{"key":"1321_CR16","doi-asserted-by":"publisher","first-page":"e0139057","DOI":"10.1371\/journal.pone.0139057","volume":"10","author":"EG Gruppen","year":"2015","unstructured":"Gruppen EG, Riphagen IJ, Connelly MA, Otvos JD, Bakker SJ, Dullaart RP. GlycA, a pro-inflammatory glycoprotein biomarker, and incident cardiovascular disease: relationship with C-reactive protein and renal function. PLoS ONE. 2015;10:e0139057.","journal-title":"PLoS ONE"},{"key":"1321_CR17","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1373\/clinchem.2016.255828","volume":"62","author":"DA Duprez","year":"2016","unstructured":"Duprez DA, Otvos J, Sanchez OA, Mackey RH, Tracy R, Jacobs DR Jr. Comparison of the predictive value of GlycA and other biomarkers of inflammation for total death, incident cardiovascular events, noncardiovascular and noncancer inflammatory-related events, and total cancer events. Clin Chem. 2016;62:1020\u201331.","journal-title":"Clin Chem"},{"issue":"7","key":"1321_CR18","doi-asserted-by":"publisher","first-page":"e003822","DOI":"10.1161\/JAHA.116.003822","volume":"5","author":"AO Akinkuolie","year":"2016","unstructured":"Akinkuolie AO, Glynn RJ, Padmanabhan L, Ridker PM, Mora S. Circulating N-linked glycoprotein side-chain biomarker, rosuvastatin therapy, and incident cardiovascular disease: an analysis from the JUPITER trial. J Am Heart Assoc. 2016;5(7):e003822.","journal-title":"J Am Heart Assoc"},{"key":"1321_CR19","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1161\/ATVBAHA.115.305635","volume":"35","author":"AO Akinkuolie","year":"2015","unstructured":"Akinkuolie AO, Pradhan AD, Buring JE, Ridker PM, Mora S. Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2015;35:1544\u201350.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1321_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cca.2015.11.001","volume":"452","author":"MA Connelly","year":"2016","unstructured":"Connelly MA, Gruppen EG, Wolak-Dinsmore J, Matyus SP, Riphagen IJ, Shalaurova I, Bakker SJ, Otvos JD, Dullaart RP. GlycA, a marker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study. Clin Chim Acta. 2016;452:10\u20137.","journal-title":"Clin Chim Acta"},{"key":"1321_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13075-016-0982-5","volume":"18","author":"DB Bartlett","year":"2016","unstructured":"Bartlett DB, Connelly MA, AbouAssi H, Bateman LA, Tune KN, Huebner JL, Kraus VB, Winegar DA, Otvos JD, Kraus WE, Huffman KM. A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls. Arthritis Res Ther. 2016;18:86.","journal-title":"Arthritis Res Ther"},{"key":"1321_CR22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1177\/0961203315617842","volume":"25","author":"CP Chung","year":"2016","unstructured":"Chung CP, Ormseth MJ, Connelly MA, Oeser A, Solus JF, Otvos JD, Raggi P, Stein CM. GlycA, a novel marker of inflammation, is elevated in systemic lupus erythematosus. Lupus. 2016;25:296\u2013300.","journal-title":"Lupus"},{"key":"1321_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3899\/jrheum.150437","volume":"43","author":"L Durcan","year":"2016","unstructured":"Durcan L, Winegar DA, Connelly MA, Otvos JD, Magder LS, Petri M. Longitudinal evaluation of lipoprotein variables in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy. J Rheumatol. 2016;43:745\u201350.","journal-title":"J Rheumatol"},{"key":"1321_CR24","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1161\/CIRCRESAHA.116.309637","volume":"119","author":"AA Joshi","year":"2016","unstructured":"Joshi AA, Lerman JB, Aberra TM, Afshar M, Teague HL, Rodante JA, Krishnamoorthy P, Ng Q, Aridi TZ, Salahuddin T, et al. GlycA is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis. Circ Res. 2016;119:1242\u201353.","journal-title":"Circ Res"},{"key":"1321_CR25","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","volume":"107","author":"DH Solomon","year":"2003","unstructured":"Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303\u20137.","journal-title":"Circulation"},{"key":"1321_CR26","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/ard.2003.018101","volume":"63","author":"C Turesson","year":"2004","unstructured":"Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis. 2004;63:952\u20135.","journal-title":"Ann Rheum Dis"},{"key":"1321_CR27","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/art.24092","volume":"59","author":"JA Avina-Zubieta","year":"2008","unstructured":"Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690\u20137.","journal-title":"Arthritis Rheum"},{"key":"1321_CR28","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/rheumatology\/kep252","volume":"48","author":"C Meune","year":"2009","unstructured":"Meune C, Touze E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50\u00a0years: a systematic review and meta-analysis of cohort studies. Rheumatol. 2009;48:1309\u201313.","journal-title":"Rheumatol"},{"key":"1321_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.acvd.2010.03.007","volume":"103","author":"C Meune","year":"2010","unstructured":"Meune C, Touze E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in rheumatoid arthritis: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis. 2010;103:253\u201361.","journal-title":"Arch Cardiovasc Dis"},{"key":"1321_CR30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/HJH.0b013e32835bcce1","volume":"31","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31:433\u201342.","journal-title":"J Hypertens"},{"key":"1321_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00403-016-1712-1","volume":"309","author":"L Raaby","year":"2017","unstructured":"Raaby L, Ahlehoff O, de Thurah A. Psoriasis and cardiovascular events: updating the evidence. Arch Dermatol Res. 2017;309:225\u20138.","journal-title":"Arch Dermatol Res"},{"key":"1321_CR32","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/ard.2010.135871","volume":"70","author":"E Myasoedova","year":"2011","unstructured":"Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, Gabriel SE. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1321_CR33","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1093\/rheumatology\/keu224","volume":"53","author":"E Choy","year":"2014","unstructured":"Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford). 2014;53:2143\u201354.","journal-title":"Rheumatology (Oxford)"},{"key":"1321_CR34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s11882-014-0497-6","volume":"15","author":"A Bag-Ozbek","year":"2015","unstructured":"Bag-Ozbek A, Giles JT. Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship? Curr Allergy Asthma Rep. 2015;15:497.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"5","key":"1321_CR35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/rheumatology\/kew440","volume":"56","author":"E Alemao","year":"2017","unstructured":"Alemao E, Cawston H, Bourhis F, Al M, Rutten-van Molken M, Liao KP, Solomon DH. Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis. Rheumatol. 2017;56(5):777\u201386.","journal-title":"Rheumatol"},{"key":"1321_CR36","doi-asserted-by":"publisher","first-page":"e0165615","DOI":"10.1371\/journal.pone.0165615","volume":"11","author":"PD Chandler","year":"2016","unstructured":"Chandler PD, Akinkuolie AO, Tobias DK, Lawler PR, Li C, Moorthy MV, Wang L, Duprez DA, Jacobs DR, Glynn RJ, et al. Association of N-linked glycoprotein acetyls and colorectal cancer incidence and mortality. PLoS ONE. 2016;11:e0165615.","journal-title":"PLoS ONE"},{"issue":"Pt 4","key":"1321_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1177\/000456329303000404","volume":"30","author":"GH Clark","year":"1993","unstructured":"Clark GH, Fraser CG. Biological variation of acute phase proteins. Ann Clin Biochem. 1993;30(Pt 4):373\u20136.","journal-title":"Ann Clin Biochem"},{"key":"1321_CR38","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/aje\/kwg135","volume":"158","author":"W Koenig","year":"2003","unstructured":"Koenig W, Sund M, Frohlich M, Lowel H, Hutchinson WL, Pepys MB. Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the Monica Augsburg studies, 1984 and 1987. Am J Epidemiol. 2003;158:357\u201364.","journal-title":"Am J Epidemiol"},{"key":"1321_CR39","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.atherosclerosis.2012.07.017","volume":"224","author":"EM DeGoma","year":"2012","unstructured":"DeGoma EM, French B, Dunbar RL, Allison MA, Mohler ER 3rd, Budoff MJ. Intraindividual variability of C-reactive protein: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2012;224:274\u20139.","journal-title":"Atherosclerosis"},{"key":"1321_CR40","doi-asserted-by":"publisher","first-page":"e60759","DOI":"10.1371\/journal.pone.0060759","volume":"8","author":"P Bogaty","year":"2013","unstructured":"Bogaty P, Dagenais GR, Joseph L, Boyer L, Leblanc A, Belisle P, Brophy JM. Time variability of C-reactive protein: implications for clinical risk stratification. PLoS ONE. 2013;8:e60759.","journal-title":"PLoS ONE"},{"issue":"11","key":"1321_CR41","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/S0735-1097(17)34458-3","volume":"69","author":"JB Muhlestein","year":"2017","unstructured":"Muhlestein JB, Mays H, Galenko O, Knowlton K, Otvos JD, Connelly MA, Lappe D, Anderson J. Both the novel NMR biomarker of inflammation, GlycA, and hs-CRP are independent and additive predictors of future cardiovascular events among patients undergoing coronary angiography: results from the Intermountain Heart Collaborative Study. J Amer Coll Cardiol. 2017;69(11):1069.","journal-title":"J Amer Coll Cardiol"},{"key":"1321_CR42","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM199902113400607","volume":"340","author":"C Gabay","year":"1999","unstructured":"Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448\u201354.","journal-title":"N Engl J Med"},{"issue":"4","key":"1321_CR43","first-page":"000050","volume":"2","author":"MA Connelly","year":"2015","unstructured":"Connelly MA, Winegar DW, Shalaurova I, Otvos JD. Nuclear magnetic resonance measured serum biomarkers and type 2 diabetes risk stratification. J Diab Metab Disord Contr. 2015;2(4):000050.","journal-title":"J Diab Metab Disord Contr"},{"key":"1321_CR44","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1161\/CIRCGENETICS.114.000216","volume":"8","author":"P Soininen","year":"2015","unstructured":"Soininen P, Kangas AJ, Wurtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet. 2015;8:192\u2013206.","journal-title":"Circ Cardiovasc Genet"},{"key":"1321_CR45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.metabol.2016.12.015","volume":"69","author":"K Mokkala","year":"2017","unstructured":"Mokkala K, Pellonpera O, Roytio H, Pussinen P, Ronnemaa T, Laitinen K. Increased intestinal permeability, measured by serum zonulin, is associated with metabolic risk markers in overweight pregnant women. Metabolism. 2017;69:43\u201350.","journal-title":"Metabolism"},{"key":"1321_CR46","doi-asserted-by":"publisher","first-page":"e1001606","DOI":"10.1371\/journal.pmed.1001606","volume":"11","author":"K Fischer","year":"2014","unstructured":"Fischer K, Kettunen J, Wurtz P, Haller T, Havulinna AS, Kangas AJ, Soininen P, Esko T, Tammesoo ML, Magi R, et al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. PLoS Med. 2014;11:e1001606.","journal-title":"PLoS Med"},{"key":"1321_CR47","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119\u201331.","journal-title":"N Engl J Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-017-1321-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-017-1321-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-017-1321-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T13:58:16Z","timestamp":1659707896000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-017-1321-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,27]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1321"],"URL":"https:\/\/doi.org\/10.1186\/s12967-017-1321-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,27]]},"assertion":[{"value":"5 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"219"}}